Ulf Grawunder
Chief Executive Officer & Co-Founder T-CURX
Ulf is a co-founder of T-CURX and has over 20 years of experience in founding and building Biotech companies from the ground up and bringing them to an exit. Prior to assuming the role of CEO at T-CURX in 2022, Ulf was CEO and Board member at NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which was focused on the development of antibody drug conjugates. Prior to T-CURX he had co-founded 4-Antibody AG in 2004 and NBE-Therapeutics in 2012. Ulf holds a Diploma in Biochemistry from the University of Bayreuth and obtained his PhD from the University of Basel in 1994.
Seminars
Applying key learnings from ex vivo developments to optimise indication selection, targeting strategies, and clinical translation for in vivo approaches
Discussing the key scientific, regulatory considerations to streamline the integration of in vivo cell therapies into the pipeline
